Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on acquiring, in-licensing, developing, and commercializing novel medicines for patients living with rare diseases.
The company follows a patient-first approach, emphasizing on educating rare disease communities on access to care and adherence.
With a profitable track record and a patient-driven strategy, Catalyst Pharmaceuticals aims to forge new paths for rare disease patients.
Catalyst Pharmaceuticals has a strong focus on rare disease therapeutics, providing innovative solutions and personalized support programs.
Through a commitment to patient-centric care and a proven track record of growth, Catalyst Pharmaceuticals is dedicated to enhancing the lives of individuals with rare diseases.
Only Evidence-Based Treatment
Catalyst Pharmaceuticals offers the only evidence-based approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) and a differentiated corticosteroid treatment for Duchenne Muscular Dystrophy (DMD), setting it apart in the rare disease treatment landscape.
High Prescription Compliance
The company's bespoke patient programs have achieved over 90% prescription compliance for FIRDAPSE and AGAMREE, indicating robust patient engagement and support efforts by Catalyst Pharmaceuticals.
Proven Growth Strategy
Catalyst has implemented a successful buy-and-build approach, acquiring, launching, and growing products with a remarkable 37% compound annual growth rate (CAGR) since the launch of FIRDAPSE through YE 2024, demonstrating strategic effectiveness.
Financial Stability
With seven consecutive years of profitability, consistent double-digit topline growth, and a substantial financial cushion of over $700 million in cash & cash equivalents with no funded debt as of December 31, 2025, Catalyst Pharmaceuticals stands out for its solid financial foundation.
Personalized Patient Support
Through initiatives such as the Patient HUB, Patient Access Liaisons, patient ambassador programs, and high-touch specialty pharmacy services, Catalyst Pharmaceuticals focuses on accelerating access, ensuring compliance, and optimizing care for rare disease patients, enhancing treatment outcomes.
- Catalyst Pharmaceuticals is strategically positioned to deliver innovative solutions and personalized support programs to patients with rare diseases, offering a clear acquisition strategy to complement organic growth and reinforce its market presence.
- The company's financial stability and impressive growth trajectory not only cement its position as a respected partner in the rare disease therapeutics market but also create substantial value and sustainable outcomes for patients, reflecting its strategic resilience and commitment to rare disease communities.
Catalyst Pharmaceuticals, with its unwavering dedication to patient-centric care, proven growth trajectory, and strategic focus on supporting rare disease communities, continues to advance its mission of improving the lives of patients with rare diseases through innovative treatments and personalized support programs.